Results 111 to 120 of about 15,755 (201)

Mechanisms of action and clinical development of elotuzumab [PDF]

, 2017
Colonna, Marco, Ritchie, David
core   +2 more sources

Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis

Practical Laboratory Medicine
Therapeutic monoclonal antibodies (t-mAbs), such as daratumumab (anti-CD38), are increasingly used in plasma cell disorders including systemic AL amyloidosis.
Hou-Long Luo, Anping Xu, Ling Ji
doaj   +1 more source

Real-world drug regimes for multiple myeloma in a Swiss population (2012 to 2017) : cost-outcome description [PDF]

, 2019
Blozik, Eva, Eichler, Klaus, Rapold, Ronald, Reich, Oliver, Wieser, Simon   +4 more
core   +1 more source

Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes [PDF]

Over the past few years, many new treatments have been approved for patients with multiple myeloma (MM) and these have improved outcomes like response rates and survival.
Armeni, Patrizio, Bringhen, Sara, Entrala Cerezo, Cristina, Mendes, João, Petrucci, Maria Teresa   +4 more
core   +1 more source

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Advanced Science
First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects.
Yueh‐Hsiang Yu, Wei‐Ting Tian, Cédric Grauffel, Wei‐Chen Lin, Ming‐Yu Hsieh, Pei‐Wen Wu, Hui‐Ju Lee, Chi‐Jiun Peng, Pei‐Hsuan Lin, Hsing‐Mao Chu, Carmay Lim, Tse Wen Chang   +11 more
doaj   +1 more source

Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up

Research and Practice in Thrombosis and Haemostasis
Background: Management of patients with refractory or frequently relapsing (r/r) immune thrombotic thrombocytopenic purpura (iTTP) remains challenging, with no established consensus on optimal therapeutic strategies.
Roman Schimmer, Jana van den Berg, Marissa Schraner, Alice Trinchero, Andreas Holbro, Johanna A. Kremer Hovinga, Jan-Dirk Studt   +6 more
doaj   +1 more source

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

eJHaem
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy.
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema   +5 more
doaj   +1 more source

P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA

Haematologica
Introduction In patients (pts) with multiple myeloma (MM), the combination of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) is a standard of care, approved both for frontline treatment of non-transplant eligible (NTE) pts and in the relapsed ...
L. Cani, A. Di Nicola, A. Evangelista, I. Delle Donne, G. Bertuglia, A. Casson, M. D’agostino, F. Gay, A. Larocca, E. Marchetti, R. Mina, S. Oliva, T. Picardi, B. Bruno, S. Bringhen, G. Benevolo   +15 more
doaj  

Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy. [PDF]

Res Pract Thromb Haemost
Coppo P.
europepmc   +1 more source

Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]

, 2019
al., et, Vij, Ravi
core   +1 more source